Human tonsil‑derived mesenchymal stromal cells enhanced myelopoiesis in a mouse model of allogeneic bone marrow transplantation

Ryu,Jung‑Hwa; Park,Minhwa; Kim,Bo‑Kyung; Kim,Yu‑Hee; Woo,So‑Youn; Ryu,Kyung‑Ha

doi:10.3892/mmr.2016.5604

Human tonsil‑derived mesenchymal stromal cells enhanced myelopoiesis in a mouse model of allogeneic bone marrow transplantation

Authors:
- Jung‑Hwa Ryu
- Minhwa Park
- Bo‑Kyung Kim
- Yu‑Hee Kim
- So‑Youn Woo
- Kyung‑Ha Ryu
View Affiliations

Affiliations: Department of Microbiology, School of Medicine, Global Top 5 Research Program, Ewha Womans University, Seoul 158‑710, Republic of Korea, Department of Pediatrics, School of Medicine, Global Top 5 Research Program, Ewha Womans University, Seoul 158‑710, Republic of Korea
Published online on: August 8, 2016 https://doi.org/10.3892/mmr.2016.5604
Pages: 3045-3051
Copyright: © Ryu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mesenchymal stromal cells (MSCs) have therapeutic potential for repairing tissue damage and are involved in immune regulation. MSCs are predominantly isolated from bone marrow (BM), adipose tissue or placental tissue. Further to these well‑known sources, the isolation of MSCs from human tonsils was previously reported. The aim of the present study was to investigate a potential role for tonsil‑derived MSCs (T‑MSCs) in BM reconstitution and application towards supplementing hematopoiesis in a mouse model of BM transplantation (BMT). Eight‑week‑old BALB/c female mice received 80 mg/kg busulfan (Bu)/200 mg/kg cyclophosphamide (Cy) conditioning chemotherapy for BM ablation. Subsequently, human T‑MSCs were injected into the Bu/Cy‑treated mice with or without BM cells (BMCs) obtained from allogeneic C57BL/6 male mice. After 3 weeks, peripheral blood and BM was collected for analysis. The red blood cell count in the group that received BMCs had almost returned to normal, whereas mononuclear cell counts and BM cellularity were most improved in the T‑MSCs + BMCs group. These results indicate that the T‑MSCs enhanced myelopoiesis in the allogeneic BMT mouse model, as evidenced by the restoration of BM with hematopoietic cells, as well as increased myeloid colony formation in vitro. Therefore, T‑MSCs may provide a source of MSCs to facilitate myelopoiesis and megakaryocytosis following BMT.

View Figures

View References

1	Dexter TM, Spooncer E, Schofield R, Lord BI and Simmons P: Haemopoietic stem cells and the problem of self-renewal. Blood Cells. 10:315–339. 1984.PubMed/NCBI
2	Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S and Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science. 284:143–147. 1999. View Article : Google Scholar : PubMed/NCBI
3	Toma C, Pittenger MF, Cahill KS, Byrne BJ and Kessler PD: Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 105:93–98. 2002. View Article : Google Scholar : PubMed/NCBI
4	Sanchez-Ramos J, Song S, Cardozo-Pelaez F, Hazzi C, Stedeford T, Willing A, Freeman TB, Saporta S, Janssen W, Patel N, et al: Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol. 164:247–256. 2000. View Article : Google Scholar : PubMed/NCBI
5	Kim EJ, Kim N and Cho SG: The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation. Exp Mol Med. 45:e22013. View Article : Google Scholar : PubMed/NCBI
6	Kern S, Eichler H, Stoeve J, Klüter H and Bieback K: Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 24:1294–1301. 2006. View Article : Google Scholar : PubMed/NCBI
7	Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, Ljungman P, Lönnies H, Nava S and Ringdén O: Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia. 21:1733–1738. 2007. View Article : Google Scholar : PubMed/NCBI
8	Macmillan ML, Blazar BR, DeFor TE and Wagner JE: Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: Results of a phase I–II clinical trial. Bone Marrow Transplant. 43:447–454. 2009. View Article : Google Scholar
9	Joo SY, Cho KA, Jung YJ, Kim HS, Park SY, Choi YB, Hong KM, Woo SY, Seoh JY, Cho SJ and Ryu KH: Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner. Cytotherapy. 12:361–370. 2010. View Article : Google Scholar : PubMed/NCBI
10	Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, et al: Developmental Committee of the European Group for Blood and Marrow Transplatation: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet. 371:1579–1586. 2008. View Article : Google Scholar : PubMed/NCBI
11	Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M and Ringdén O: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 363:1439–1441. 2004. View Article : Google Scholar : PubMed/NCBI
12	Dalle Carbonare L, Valenti MT, Zanatta M, Donatelli L and Lo Cascio V: Circulating mesenchymal stem cells with abnormal osteogenic differentiation in patients with osteoporosis. Arthritis Rheum. 60:3356–3365. 2009. View Article : Google Scholar : PubMed/NCBI
13	Huang GT, Gronthos S and Shi S: Mesenchymal stem cells derived from dental tissues vs. those from other sources: Their biology and role in regenerative medicine. J Dent Res. 88:792–806. 2009. View Article : Google Scholar : PubMed/NCBI
14	Blazar BR, Murphy WJ and Abedi M: Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 12:443–458. 2012. View Article : Google Scholar : PubMed/NCBI
15	Almeida-Porada G, Flake AW, Glimp HA and Zanjani ED: Cotransplantation of stroma results in enhancement of engraftment and early expression of donor hematopoietic stem cells in utero. Exp Hematol. 27:1569–1575. 1999. View Article : Google Scholar : PubMed/NCBI
16	Nolta JA, Hanley MB and Kohn DB: Sustained human hematopoiesis in immunodeficient mice by cotransplantation of marrow stroma expressing human interleukin-3: Analysis of gene transduction of long-lived progenitors. Blood. 83:3041–3051. 1994.PubMed/NCBI
17	Angelopoulou M, Novelli E, Grove JE, Rinder HM, Civin C, Cheng L and Krause DS: Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice. Exp Hematol. 31:413–420. 2003. View Article : Google Scholar : PubMed/NCBI
18	Ryu KH, Cho KA, Park HS, Kim JY, Woo SY, Jo I, Choi YH, Park YM, Jung SC and Chung SM: Tonsil-derived mesenchymal stromal cells: Evaluation of biologic, immunologic and genetic factors for successful banking. Cytotherapy. 14:1193–1202. 2012. View Article : Google Scholar : PubMed/NCBI
19	Kim SJ, Park MH, Moon HJ, Park JH, Ko Y and Jeong B: Polypeptide thermogels as a three dimensional culture scaffold for hepatogenic differentiation of human tonsil-derived mesenchymal stem cells. ACS Appl Mater Interfaces. 6:17034–17043. 2014. View Article : Google Scholar : PubMed/NCBI
20	Lechler RI, Sykes M, Thomson AW and Turka LA: Organ transplantation - how much of the promise has been realized? Nat Med. 11:605–613. 2005. View Article : Google Scholar : PubMed/NCBI
21	Bluestone JA, Thomson AW, Shevach EM and Weiner HL: What does the future hold for cell-based tolerogenic therapy? Nat Rev Immunol. 7:650–654. 2007. View Article : Google Scholar : PubMed/NCBI
22	Kupcova Skalnikova H: Proteomic techniques for characterisation of mesenchymal stem cell secretome. Biochimie. 95:2196–2211. 2013. View Article : Google Scholar : PubMed/NCBI
23	Adler BJ, Kaushansky K and Rubin CT: Obesity-driven disruption of haematopoiesis and the bone marrow niche. Nat Rev Endocrinol. 10:737–748. 2014. View Article : Google Scholar : PubMed/NCBI
24	Lai RC, Tan SS, Teh BJ, Sze SK, Arslan F, de Kleijn DP, Choo A and Lim SK: Proteolytic potential of the MSC exosome proteome: Implications for an exosome-mediated delivery of therapeutic proteasome. Int J Proteomics. 2012:9719072012. View Article : Google Scholar : PubMed/NCBI
25	Ranganath SH, Levy O, Inamdar MS and Karp JM: Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell. 10:244–258. 2012. View Article : Google Scholar : PubMed/NCBI
26	Le Blanc K and Pittenger M: Mesenchymal stem cells: Progress toward promise. Cytotherapy. 7:36–45. 2005. View Article : Google Scholar : PubMed/NCBI